Celldex Therapeutics presented data on new product candidate CDX-1140 at the American Society of Hematology on Saturday.
CDX-1140 is a fully human antibody targeted to CD40 that has demonstrated potent agonist and anti-lymphoma activity. CD40 is a key activator of the immune response and is expressed on many cancer cells.
Celldex is currently performing manufacturing and Investigative New Drug-enabling studies to support phase 1 dose-escalation studies of CDX-1140. The company believes that the potential for CDX-1140 will be best defined in combination studies with other immunotherapies or conventional cancer treatments. CDX-1140 is expected to be ready to enter clinical studies in patients with advanced cancers, including lymphoma, in 2017.